OptimizeRx (NASDAQ:OPRX) Receives “Buy” Rating from B. Riley Financial

B. Riley Financial reaffirmed their buy rating on shares of OptimizeRx (NASDAQ:OPRX) in a report published on Friday,Benzinga reports. They currently have a $11.00 price target on the stock, down from their previous price target of $28.00.

Several other research analysts also recently issued reports on the stock. Stifel Nicolaus lowered their price objective on shares of OptimizeRx from $21.00 to $17.00 and set a “buy” rating on the stock in a research report on Friday. Wall Street Zen raised shares of OptimizeRx from a “buy” rating to a “strong-buy” rating in a report on Sunday, December 14th. Citizens Jmp raised their price target on OptimizeRx from $23.00 to $24.00 and gave the stock a “market outperform” rating in a report on Friday, November 7th. Weiss Ratings reissued a “sell (d+)” rating on shares of OptimizeRx in a report on Monday, December 22nd. Finally, Stephens reduced their price objective on OptimizeRx from $17.00 to $10.00 and set an “equal weight” rating for the company in a research note on Friday. Six analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, OptimizeRx currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.57.

OptimizeRx Stock Performance

NASDAQ OPRX traded down $0.79 on Friday, reaching $6.74. The stock had a trading volume of 2,099,710 shares, compared to its average volume of 437,141. The stock has a market cap of $125.63 million, a P/E ratio of 25.92 and a beta of 1.20. OptimizeRx has a 12-month low of $3.99 and a 12-month high of $22.25. The business’s 50-day moving average price is $10.52 and its 200 day moving average price is $14.73. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.05 and a current ratio of 3.05.

OptimizeRx (NASDAQ:OPRX) last announced its earnings results on Saturday, January 31st. The company reported $0.51 earnings per share (EPS) for the quarter. OptimizeRx had a net margin of 4.69% and a return on equity of 10.81%. As a group, equities analysts expect that OptimizeRx will post -0.33 earnings per share for the current year.

OptimizeRx declared that its Board of Directors has initiated a stock repurchase plan on Thursday, March 5th that permits the company to repurchase $10.00 million in outstanding shares. This repurchase authorization permits the company to repurchase up to 6.8% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s board believes its stock is undervalued.

Institutional Trading of OptimizeRx

Several hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. lifted its stake in shares of OptimizeRx by 15.0% in the 3rd quarter. Vanguard Group Inc. now owns 1,059,109 shares of the company’s stock worth $21,712,000 after acquiring an additional 138,224 shares during the period. Royce & Associates LP increased its stake in shares of OptimizeRx by 0.7% during the fourth quarter. Royce & Associates LP now owns 682,030 shares of the company’s stock worth $8,362,000 after acquiring an additional 4,700 shares during the period. Kennedy Capital Management LLC raised its holdings in OptimizeRx by 42.8% during the third quarter. Kennedy Capital Management LLC now owns 674,918 shares of the company’s stock worth $13,836,000 after purchasing an additional 202,446 shares in the last quarter. Rice Hall James & Associates LLC raised its holdings in OptimizeRx by 8.2% during the fourth quarter. Rice Hall James & Associates LLC now owns 590,674 shares of the company’s stock worth $7,242,000 after purchasing an additional 44,858 shares in the last quarter. Finally, Parkman Healthcare Partners LLC lifted its position in OptimizeRx by 0.4% in the third quarter. Parkman Healthcare Partners LLC now owns 509,611 shares of the company’s stock valued at $10,447,000 after purchasing an additional 2,188 shares during the period. Institutional investors and hedge funds own 76.47% of the company’s stock.

OptimizeRx News Roundup

Here are the key news stories impacting OptimizeRx this week:

• Positive Sentiment: Q4 earnings and revenue beat expectations — OPRX reported stronger-than-expected results (EPS and revenue topped consensus), supporting the company’s underlying growth narrative. Q4 Results
• Positive Sentiment: Board authorized a $10.0M share repurchase program (up to ~6.8% of shares), a shareholder-friendly move that typically supports share price over time by reducing float. Buyback Announcement
• Neutral Sentiment: Roth MKM lowered its price target from $32 to $18 but kept a “buy” rating — still a materially higher target than current levels, creating mixed signals (cut in optimism but continued buy conviction). Roth MKM PT Change
• Neutral Sentiment: Multiple brief trading halts for OPRX were reported today due to LULD pauses — technical market safeguards that can amplify volatility but do not convey fundamental news.
• Negative Sentiment: FY2026 revenue guidance came in at $109M–$114M versus consensus near $122M — a notable shortfall that likely drove investor disappointment and downward pressure on the stock. Guidance Story
• Negative Sentiment: B. Riley reaffirmed its buy rating but cut its price target from $28 to $11 — another analyst reduction that removes prior upside and likely contributed to selling pressure. B. Riley PT Cut
• Negative Sentiment: Stephens trimmed its target to $10 and set an “equal weight” rating, signaling a more cautious view and reducing analyst-driven upside expectations. Stephens PT Change

OptimizeRx Company Profile

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.